RioMSK002

RioMSK002 is an investigational exosome-based therapy being developed by Rion, a clinical-stage regenerative medicine company. It is part of Rion's musculoskeletal therapeutic pipeline and is based on their Purified Exosome Product (PEP) technology platform, which aims to harness the therapeutic potential of exosomes for regenerative medicine applications. While specific details about its mechanism of action or targeted indications are not provided in the available sources, it is grouped with other musculoskeletal candidates such as RioMSK001, which targets osteoarthritis and utilizes intraarticular administration of exosomes[1][2]. The PEP technology suggests that RioMSK002 likely functions through delivery of bioactive molecules via exosomes to promote tissue repair or regeneration.